Stay updated with breaking news from I Mab. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ --I-Mab ("I-Mab" or the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and...
I-Mab (NASDAQ:IMAB – Get Rating) has been given an average recommendation of “Buy” by the eight brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12-month price objective among brokerages that have […]
I-Mab (NASDAQ:IMAB – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday, Zacks.com reports. According to Zacks, “I-Mab is a clinical stage biopharmaceutical company. It engages in discovery, development and commercialization of biologics to treat diseases with […]
Merck's former China head will return to the Big Pharma to lead international human health operations after a short stint at a Chinese company.
A number of research firms have changed their ratings and price targets for I-Mab (NASDAQ: IMAB): 4/8/2022 – I-Mab was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “I-Mab is a clinical stage biopharmaceutical company. It engages in discovery, development and commercialization of biologics to […]